STOCK TITAN

Lyra Therapeutics Inc - LYRA STOCK NEWS

Welcome to our dedicated news page for Lyra Therapeutics (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lyra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lyra Therapeutics's position in the market.

Rhea-AI Summary
Lyra Therapeutics, Inc. (LYRA) reports financial results for Q4 and full year 2023. The company anticipates topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS patients in Q2 2024. LYR-220 shows positive results in BEACON Phase 2 trial. The company's financials show steady growth with cash reserves to fund operations till Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
-
Rhea-AI Summary
Lyra Therapeutics, Inc. granted non-qualified stock options to 18 new non-executive employees to purchase 119,200 shares of Lyra common stock. The options have a ten-year term with an exercise price of $5.48 per share and vest over a four-year period. This move aims to incentivize new employees and align their interests with the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported positive data from the BEACON Phase 2 clinical trial of LYR-220, demonstrating statistically significant improvement in sinus opacification and symptomatic improvement in chronic rhinosinusitis (CRS) patients who have had prior ethmoid sinus surgery. The ENLIGHTEN I pivotal Phase 3 trial of LYR-210 in CRS patients who have not had ethmoid sinus surgery is fully enrolled, with topline results expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced that their President and CEO will participate in investor conferences in November. The conferences include Jefferies London Healthcare Conference 2023 on November 16th and Piper Sandler 35th Annual Healthcare Conference on November 29th. Live webcasts will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Lyra Therapeutics announces positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with chronic rhinosinusitis (CRS)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.48%
Tags
-
Rhea-AI Summary
Lyra Therapeutics, Inc. announces participation in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
conferences
Rhea-AI Summary
Lyra Therapeutics announces full enrollment of Phase 3 ENLIGHTEN I clinical trial for LYR-210 in CRS patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
-
Rhea-AI Summary
Lyra Therapeutics is making progress in its clinical trials for the treatment of chronic rhinosinusitis (CRS). The enrollment for the pivotal Phase 3 trial of LYR-210 in pre-surgical CRS patients is expected to be completed soon, with data expected in the first half of 2024. Initial topline results from the Phase 2 trial of LYR-220 in post-surgical CRS are anticipated in September 2023. The company also reported a strong balance sheet with net proceeds of $46.7 million from a private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Lyra Therapeutics Inc

Nasdaq:LYRA

LYRA Rankings

LYRA Stock Data

315.44M
26.23M
1.18%
84.67%
0.37%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Watertown

About LYRA

lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.